ONCOLYTICS BIOTECH INC 8-K

What Happened On July 13, 2026, Oncolytics Biotech Inc. filed an 8‑K and issued a press release announcing progress on its REO 033 clinical study and that the company will hold a Type D meeting with the U.S. Food and Drug Administration to discuss plans for registrational expansion and other study design elements. The filing includes the press release as an exhibit and is signed by CFO Kirk Look.

Key Details

• Date filed: July 13, 2026.
• Study referenced: REO 033.
• Regulatory action: Planned Type D meeting with the U.S. FDA to discuss registrational expansion and study design.
• Filing attachments: Press release included as Exhibit 99.1; report signed by Chief Financial Officer Kirk Look.

Why It Matters This filing informs investors that Oncolytics is engaging directly with the FDA about transitioning part of the REO 033 program toward a registrational path, which could affect the timeline and regulatory requirements for later-stage development. The planned Type D meeting is a formal step in clarifying study design and endpoints that regulators would expect for potential approval, making it a material update for investors tracking clinical progress and regulatory risk.